ADXS – HPV is patented in Japan

Source: China Council for the promotion of drugs March 20, 2014 Eastern time March 18, 2014 morning, advaxis, a clinical stage biotechnology company that develops the next generation of cancer immunotherapy, announced that ADXS – HPV, a product used to treat cervical cancer, was patented in Japan until 2028 The company said the Japanese Patent Office issued the major patent under the title of "composition and methods for enhancing immunogenicity of antigens" The patent (Patent No 5479918) claims to include the use of ADXS – HPV in the treatment of advanced cervical cancer until 2028 Daniel O'Connor, chief executive officer of advaxis, said, "our exclusive immunotherapy candidate, ADXS – HPV, which is used to treat patients with advanced cervical cancer, has been patented in Japan, which is an important milestone This ADXS – HPV patent acquisition in Japan has expanded our patent portfolio, which includes more than 40 patents that have been obtained and more than 40 patents that are being applied for around the world " O'Connor added, "with patent licensing agreements with Asia, global biopharmaceutics and biocon Ltd in India, advaxis has been positioned as our global development and commercialization of immunotherapy for cervical cancer Expanding our intellectual property protection is an important part of this strategy " Original link: http://